MoneyDiscourse
← All companies

MRK

Merck & Co., Inc. · Health Care

8 quarters · 65 figures · latest Q3 FY2026 filed 2026-10-29 →

Compared

6 of 8 · select any line below to add or remove it ·

  • Sales

    $18.09bn+4.7% Y/Y

    Q3 FY2026

  • GAAP net income

    $5.07bn−12.4% Y/Y

    Q3 FY2026

  • GAAP EPS

    $2.04−12.1% Y/Y

    Q3 FY2026

  • Gross margin

    72.9%−6.2% Y/Y

    Q3 FY2026

  • Cost of sales

    $4.89bn+26.9% Y/Y

    Q3 FY2026

  • Non-GAAP Cost of sales

    $3.36bn+7.4% Y/Y

    Q3 FY2026

Reported figures

Click any line for its full history. Each figure links to the filing it was read from.

Income statement

24 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Cost of salescost_of_sales
$5.55bn$4.2bn$4.4bn$4.89bn+26.9%+11.3%
Non-GAAP Cost of salescost_of_sales_non_gaap
$3.32bn$2.94bn$3.14bn$3.36bn+7.4%+6.7%
Average Shares Outstanding Assuming Dilutiondiluted_shares
2,4882,4722,4702,478−0.8%+0.3%
GAAP EPSeps_diluted
$1.19−$1.72−$0.54$2.04−12.1%+477.8%
Income Tax Provisionincome_tax_provision
$458m$709m$654m$492m−48.6%−24.8%
GAAP net incomenet_income
$2.96bn−$4.24bn−$1.34bn$5.07bn−12.4%+479.4%
Non-GAAP net income that excludes certain itemsnet_income_non_gaap
$5.09bn−$3.16bn−$330m$6.16bn−4.5%+1966.4%
Other (income) expense, netother_income_expense_net
$432m$138m$99m$27m+111.3%−72.7%
Non-GAAP other (income) expense, netother_income_expense_net_non_gaap
$226m$318m$290m$420m+296.2%+44.8%
Research and developmentrd_expense
$3.89bn$12.59bn$9.74bn$4.54bn+7.2%−53.4%
Non-GAAP Research and developmentrd_expense_non_gaap
$3.99bn$12.56bn$9.74bn$4.53bn+13.4%−53.4%
Restructuring costsrestructuring_costs
$213m$195m$151m$184m+291.5%+21.9%
Selling, general and administrativesga_expense
$2.9bn$2.7bn$2.9bn$2.89bn+9.6%−0.6%
Non-GAAP Selling, general and administrativesga_expense_non_gaap
$2.85bn$2.67bn$2.89bn$2.86bn+10.1%−0.9%
Salestotal_revenue
$16.4bn$16.29bn$16.61bn$18.09bn+4.7%+8.9%
Non-GAAP EPS that excludes certain itemseps_non_gaap
$2.04—−$0.13$2.49−3.5%+2015.4%
Income Before Taxesincome_before_taxes
$3.42bn——$5.56bn−17.6%—
Net (Loss) Incomenet_income_total
$2.96bn—−$1.34bn—−130.2%—
(Loss) Income Before Taxespretax_income
—−$3.53bn−$683m—−113.7%+80.7%
Non-GAAP EPS that excludes certain itemseps_diluted_non_gaap
—−$1.28——−157.7%—
Net Income (Loss)net_income_including_nci
———$5.07bn−12.4%—
Non-GAAP Income Before Taxesincome_before_taxes_non_gaap————$6.91bn——
Non-GAAP income tax provisionincome_tax_provision_non_gaap———$882m———
Non-GAAP pretax incomepretax_income_non_gaap———$550m———

Segments

33 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Animal Healthanimal_health_sales
$1.51bn$1.79bn$1.78bn$1.68bn+3.8%−5.6%
BRAVECTO line of productsbravecto_sales
$222m$379m$359m$264m+0.8%−26.5%
BRIDIONbridion_sales
$499m$472m$497m$144m−67.2%−71.0%
CAPVAXIVEcapvaxive_sales
$279m$142m$184m$263m+7.8%+42.9%
Companion Animalcompanion_animal_sales
$518m$727m$734m$628m+6.1%−14.4%
GARDASIL/GARDASIL 9gardasil_sales
$1.03bn$1.07bn$1.17bn$2bn+14.1%+70.7%
JANUVIA/JANUMETjanuvia_janumet_sales
$501m$574m$429m$380m−39.1%−11.4%
Keytrudakeytruda_sales
$8.37bn$7.91bn$7.9bn$7.77bn−4.6%−1.7%
Lenvimalenvima_alliance_revenue
$272m$256m$283m$287m+11.2%+1.4%
Livestocklivestock_sales
$987m$1.06bn$1.04bn$1.05bn+2.4%+0.7%
Lynparzalynparza_alliance_revenue
$389m$341m$365m$352m−7.1%−3.6%
Other Revenuesother_revenues
$52m$146m$72m$141m+182.0%+95.8%
Pharmaceuticalpharmaceutical_sales
$14.84bn$14.35bn$14.76bn$16.27bn+4.2%+10.2%
PREVYMISprevymis_sales
$275m$272m$295m$347m+30.5%+17.6%
PROQUAD, M-M-R II and VARIVAXproquad_mmr_varivax_sales
$619m$538m$592m$730m+6.7%+23.3%
Vaxneuvancevaxneuvance_sales
$140m$202m$148m$195m−13.7%+31.8%
WELIREGwelireg_sales
$220m$199m$271m$307m+56.6%+13.3%
WINREVAIRwinrevair_sales
$467m$525m$588m$694m+92.8%+18.0%
Alliance Revenue – Reblozylreblozyl_alliance_revenue
$164m$148m—$177m+30.1%—
Keytruda Qlexkeytruda_qlex_sales
—$128m$463m$830m+16500.0%+79.3%
OHTUVAYREohtuvayre_sales
$178m$131m$204m$184m—−9.8%
Adempasadempas_sales
———$78m−4.9%—
Alliance Revenue - Adempas/Verquvoadempas_verquvo_alliance_revenue
———$118m+5.4%—
Delstrigodelstrigo_sales
———$67m−13.0%—
Dificiddificid_sales
———$14m−67.4%—
ENFLONSIAenflonsia_sales
———$187m+136.7%—
Isentress/Isentress HDisentress_sales
———$52m−36.6%—
Janumetjanumet_sales
———$194m−20.2%—
Januviajanuvia_sales
———$186m−51.3%—
Other Pharmaceuticalother_pharmaceutical_sales
———$793m−21.0%—
Total Vaccines salestotal_vaccines_sales
——$2.36bn—−0.4%—
Total Vaccines salesvaccines_sales
—$2.31bn——−11.2%—
Zerbaxazerbaxa_sales
———$90m+11.1%—

Operating

4 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
KEYTRUDA/ KEYTRUDA QLEXkeytruda_total_sales
—$8.03bn$8.37bn$8.6bn+5.6%+2.8%
LAGEVRIOlagevrio_sales
—$28m$5m$17m−87.7%+240.0%
Koselugo alliance revenuekoselugo_alliance_revenue
—$161m—$13m−93.9%—
RotaTeqrotateq_sales
—$206m—$196m−3.9%—

Margins

4 lines

LineTrendQ4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Y/YQ/Q
Effective Income Tax Rateeffective_tax_rate
13.4%−20.1%−95.9%8.9%−37.3%+109.3%
Gross margingross_margin
66.2%74.2%73.5%72.9%−6.2%−0.8%
Non-GAAP gross margingross_margin_non_gaap
79.7%81.9%81.1%81.4%−0.6%+0.4%
Non-GAAP effective income tax rateeffective_tax_rate_non_gaap
15.4%−43.5%160.3%10.9%—−93.2%

Guided vs delivered

What the company told the market to expect, against what it then reported. Its own guidance is the only benchmark here — no analyst estimates appear anywhere on this site.

Data from company filings. Not investment advice.